Koya Medical, a US-based developer of treatments for lymphedema and vein disease, received $11m yesterday in a series A round featuring Zühlke Ventures, a subsidiary of innovation service provider Zühlke.
Venture capital firm Arboretum Ventures led the round, which included Aphelion Capital, Scientific Health Development Partners, Bolt and InnerProduct Partners.
Founded in 2018, Koya has created a wearable compression system called Dayspring to treat cancer-related chronic lymphedema and venous insufficiency, and has secured US regulatory clearance for its product.
Koya’s president and CEO, Andy Doraiswamy, said: “Dayspring represents a breakthrough treatment for patients, bridging the convenience of a sleeve and the efficacy of a pump. We are excited to bring this wearable platform to patients with these debilitating chronic diseases.
“This milestone represents our entry into lymphatic and venous care and our commitment to develop innovative patient-centric solutions.”
